Moreover, these changes were observed when comparing PAK4 KO versus WT tumors, regardless of anti-PD-1 treatment status, which suggests that PAK4 inhibition alters the tumor microenvironment and facilitates the infiltration of key immune cells that are required to mount an antitumor response. This evidence concerns the gene PAK4 and neoplasm.